Literature DB >> 21855613

Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system.

Nicole M Brossier1, Steven L Carroll.   

Abstract

Neurofibromatosis type 1 (NF1), the most common genetic disorder affecting the human nervous system, is characterized by the development of multiple benign Schwann cell tumors in skin and large peripheral nerves. These neoplasms, which are termed dermal and plexiform neurofibromas respectively, have distinct clinical courses; of particular note, plexiform, but not dermal, neurofibromas often undergo malignant progression to form malignant peripheral nerve sheath tumors (MPNSTs), the most common malignancy occurring in NF1 patients. In recent years, a number of genetically engineered mouse models have been created to investigate the molecular mechanisms driving the pathogenesis of these tumors. These models have been designed to address key questions including: (1) whether NF1 loss in the Schwann cell lineage is essential for tumorigenesis; (2) what cell type(s) in the Schwann cell lineage gives rise to dermal neurofibromas, plexiform neurofibromas and MPNSTs; (3) how the tumor microenvironment contributes to neoplasia; (4) what additional mutations contribute to neurofibroma-MPNST progression; (5) what role different neurofibromin-regulated Ras proteins play in this process and (6) how dysregulated growth factor signaling facilitates PNS tumorigenesis. In this review, we summarize the major findings from each of these models and their limitations as well as how discrepancies between these models may be reconciled. We also discuss how information gleaned from these models can be synthesized to into a comprehensive model of tumor formation in peripheral nervous system and consider several of the major questions that remain unanswered about this process.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21855613      PMCID: PMC3263419          DOI: 10.1016/j.brainresbull.2011.08.005

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  95 in total

1.  Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1.

Authors:  H A Kim; N Ratner; T M Roberts; C D Stiles
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

2.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  Structure and function of phosphoinositide 3-kinases.

Authors:  M P Wymann; L Pirola
Journal:  Biochim Biophys Acta       Date:  1998-12-08

4.  Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors.

Authors:  S Birindelli; F Perrone; M Oggionni; C Lavarino; B Pasini; B Vergani; G N Ranzani; M A Pierotti; S Pilotti
Journal:  Lab Invest       Date:  2001-06       Impact factor: 5.662

5.  Age- and dose-dependent transplacental carcinogenesis by N-nitrosoethylurea in Syrian golden hamsters.

Authors:  B A Diwan; S Rehm; J M Rice
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  P110delta, a novel phosphoinositide 3-kinase in leukocytes.

Authors:  B Vanhaesebroeck; M J Welham; K Kotani; R Stein; P H Warne; M J Zvelebil; K Higashi; S Volinia; J Downward; M D Waterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

7.  c-Kit receptor expression in normal human Schwann cells and Schwann cell lines derived from neurofibromatosis type 1 tumors.

Authors:  Ian Dang; Julie K Nelson; George H DeVries
Journal:  J Neurosci Res       Date:  2005-11-15       Impact factor: 4.164

8.  Hypertrophic neuropathies and malignant peripheral nerve sheath tumors in transgenic mice overexpressing glial growth factor beta3 in myelinating Schwann cells.

Authors:  Richard P H Huijbregts; Kevin A Roth; Robert E Schmidt; Steven L Carroll
Journal:  J Neurosci       Date:  2003-08-13       Impact factor: 6.167

9.  PTEN dosage is essential for neurofibroma development and malignant transformation.

Authors:  Caroline Gregorian; Jonathan Nakashima; Sarah M Dry; P Leia Nghiemphu; Kate Barzan Smith; Yan Ao; Julie Dang; Gregory Lawson; Ingo K Mellinghoff; Paul S Mischel; Michael Phelps; Luis F Parada; Xin Liu; Michael V Sofroniew; Fritz C Eilber; Hong Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-21       Impact factor: 11.205

10.  Comparative pathology of nerve sheath tumors in mouse models and humans.

Authors:  Anat O Stemmer-Rachamimov; David N Louis; Gunnlaugur P Nielsen; Cristina R Antonescu; Alexander D Borowsky; Roderick T Bronson; Dennis K Burns; Pascale Cervera; Margaret E McLaughlin; Guido Reifenberger; Michael C Schmale; Mia MacCollin; Richard C Chao; Karen Cichowski; Michel Kalamarides; Shanta M Messerli; Andrea I McClatchey; Michiko Niwa-Kawakita; Nancy Ratner; Karlyne M Reilly; Yuan Zhu; Marco Giovannini
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

View more
  20 in total

1.  Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.

Authors:  Edwin Jousma; Tilat A Rizvi; Jianqiang Wu; David Janhofer; Eva Dombi; Richard S Dunn; Mi-Ok Kim; Andrea R Masters; David R Jones; Timothy P Cripe; Nancy Ratner
Journal:  Pediatr Blood Cancer       Date:  2015-04-22       Impact factor: 3.167

2.  Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma.

Authors:  Angela C Hirbe; Sonika Dahiya; Christopher A Miller; Tiandao Li; Robert S Fulton; Xiaochun Zhang; Sandra McDonald; Katherine DeSchryver; Eric J Duncavage; Jessica Walrath; Karlyne M Reilly; Haley J Abel; Melike Pekmezci; Arie Perry; Timothy J Ley; David H Gutmann
Journal:  Clin Cancer Res       Date:  2015-04-29       Impact factor: 12.531

3.  Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Authors:  Syed J Kazmi; Stephanie J Byer; Jenell M Eckert; Amy N Turk; Richard P H Huijbregts; Nicole M Brossier; William E Grizzle; Fady M Mikhail; Kevin A Roth; Steven L Carroll
Journal:  Am J Pathol       Date:  2013-01-13       Impact factor: 4.307

4.  Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

Authors:  Slawomir Antoszczyk; Melanie Spyra; Victor Felix Mautner; Andreas Kurtz; Anat O Stemmer-Rachamimov; Robert L Martuza; Samuel D Rabkin
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

5.  Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway.

Authors:  Juan Mo; Jean-Philippe Brosseau; Zhiguo Chen; Tracey Shipman; Yong Wang; Chung-Ping Liao; Jonathan M Cooper; Robert J Allaway; Sara J C Gosline; Justin Guinney; Thomas J Carroll; Lu Q Le
Journal:  Cancer Discov       Date:  2018-10-22       Impact factor: 39.397

Review 6.  From neurodevelopment to neurodegeneration: the interaction of neurofibromin and valosin-containing protein/p97 in regulation of dendritic spine formation.

Authors:  Yi-Ping Hsueh
Journal:  J Biomed Sci       Date:  2012-03-26       Impact factor: 8.410

7.  Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.

Authors:  Adrienne L Watson; Leah K Anderson; Andrew D Greeley; Vincent W Keng; Eric P Rahrmann; Amanda L Halfond; Natasha M Powell; Margaret H Collins; Tilat Rizvi; Christopher L Moertel; Nancy Ratner; David A Largaespada
Journal:  Oncotarget       Date:  2014-03-30

8.  Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors.

Authors:  Su-Jin Park; Birgit Sawitzki; Lan Kluwe; Victor F Mautner; Nikola Holtkamp; Andreas Kurtz
Journal:  BMC Med       Date:  2013-04-23       Impact factor: 8.775

9.  Mouse models of sarcomas: critical tools in our understanding of the pathobiology.

Authors:  Sean M Post
Journal:  Clin Sarcoma Res       Date:  2012-10-04

Review 10.  Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms.

Authors:  Jody F Longo; Shannon M Weber; Brittany P Turner-Ivey; Steven L Carroll
Journal:  Adv Anat Pathol       Date:  2018-09       Impact factor: 4.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.